14.3 Weight Reduction and Long-term Maintenance Study of WEGOVY Injection in Pediatric Patients Aged 12 Years and Older with Obesity SPL UNCLASSIFIED SECTION Overview of Clinical Trial in Pediatric Patients WEGOVY injection was evaluated to reduce excess body weight in pediatric patients aged 12 years of age and older with obesity in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to 95th percentile standardized for age and sex (Study 10) (NCT#04102189)
How to Manage and Reduce Side Effects of Tirzepatide Adjusting Dosage and Timing Starting Tirzepatide at a low dose and gradually increasing it can help minimize side effects, especially gastrointestinal ones
Demyelination of brain cells is commonly seen in dementia patients
Specifically, GIP and GLP-1 receptor agonists affect the areas of your brain that help regulate feelings of hunger, as well as cravings for food
Mounjaro slows gastric emptying, so large, fatty or very rich meals may sit heavily and worsen nausea, burping or heartburn